Development of a predictive model for eosinophilia in patients treated with ampicillin/sulbactam or piperacillin/tazobactam
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70368 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Sohyun Moon und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Kangwon National University, Chuncheon-si, Republic of Korea. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Piperacillin, Tazobactam Drug Combination, Eosinophilia, beta-Lactamase Inhibitors. Die Arbeit nennt 37 Literaturangaben. Gefördert von: 2024 Research Grant from Kangwon National University.
Abstract (Originalsprache)
Aim
We aim to identify risk factors for antibiotic‐induced eosinophilia in hospitalized patients receiving penicillin/beta‐lactamase inhibitor therapy and to develop a machine learning–enhanced predictive risk‐scoring model.
Methods
A retrospective cohort study was conducted involving 490 hospitalized patients treated with intravenous ampicillin/sulbactam or piperacillin/tazobactam. After applying eligibility criteria, 378 patients were included in the final analysis. Multivariate logistic regression was used to identify independent risk factors for eosinophilia, which were incorporated into a clinical risk‐scoring system. To improve predictive accuracy, machine learning models including elastic net regression were developed and evaluated using five‐fold cross‐validation. Model performance was assessed using the area under the receiver operating characteristic curve (AUROC).
Results
Among the 378 patients, 27 (7.1%) developed eosinophilia. Nine independent risk factors were identified: aminoglycosides, arrhythmias, chlorpheniramine maleate, glycopeptides, levetiracetam, polystyrene sulfonate, rheumatoid arthritis, stroke and ursodeoxycholic acid. The risk score ranged from 0 to 8, corresponding to predicted eosinophilia probabilities of 3.3% to 93.8% (AUROC = 0.787). Among the machine learning approaches tested, elastic net regression achieved the highest predictive performance.
Conclusion
This study proposes a clinically applicable risk‐scoring model for predicting eosinophilia in patients treated with penicillin/beta‐lactamase inhibitors. Incorporating machine learning improved model accuracy, enabling more precise identification of high‐risk patients. The model supports proactive risk assessment and may inform tailored monitoring and intervention strategies in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Kangwon National University, Chuncheon-si, Republic of Korea.
- Department of Systems Immunology, Kangwon National University, Chuncheon-si, Republic of Korea.
- Department of Pharmacy, Kangwon National University Hospital, Chuncheon-si, Republic of Korea.
- Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon-si, Republic of Korea.
ORCID-Profile: Woorim Kim
Förderung
- 2024 Research Grant from Kangwon National University
Zitieren
APA
Moon, S., Hong, J., Lee, D. H., Kim, H. S., Nam, K. N., Jeon, Y. D., & Kim, W. (2025). Development of a predictive model for eosinophilia in patients treated with ampicillin/sulbactam or piperacillin/tazobactam. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70368
Vancouver
Moon S, Hong J, Lee DH, Kim HS, Nam KN, Jeon YD, et al. Development of a predictive model for eosinophilia in patients treated with ampicillin/sulbactam or piperacillin/tazobactam. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70368
BibTeX
@article{Moon2025,
author = {Moon, Sohyun and Hong, Jimin and Lee, Dae Hun and Kim, Hye Su and Nam, Ki Nam and Jeon, Yong Duk and Kim, Woorim},
title = {Development of a predictive model for eosinophilia in patients treated with ampicillin/sulbactam or piperacillin/tazobactam},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70368}
}
EUVIMED